Growing Use of Biosimilar in treating IBD; Efficacy and Cost-effectiveness to be Major Demand Drivers

 Inflammatory bowel disease (IBD) is an idiopathic inflammatory disease of the gastrointestinal system which is chronic in nature. The disease is of predominantly two types, Crohn’s disease and ulcerative colitis. The treatment of IBD has been transforming with new treatment alternatives in use. The ending patent period of drugs give rise to the production of similar biologics that are commercialized at a lower price than the innovator biologics. These drugs are known as biosimilars which are biologic products similar to reference biologic with no difference in terms of efficacy and safety. Research revealed that physicians stated that they would consider switching to biosimilar infliximab (IFX) for treating patients suffering from IBD. Cost utility has shown a significant shift towards medication from hospitalization, peculiarly in biologics. This has resulted in the tremendous economic burden enforced by IBD treatment. These insights are taken from the market research report titled, “Physician Perspectives 2017: Biosimilar use in IBD”, which is added in the repository of Market Research Hub (MRH) that examines the potential of biosimilars when used for treating IBD.

Request Sample Copy of the Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1918129

Biosimilars Contribute in Improving the Lives of IBD Patients

Owing to the safety and efficacy showcased by biosimilar drugs, pharmaceutical companies are looking forward to harness the potential of these drugs for treating IBD. Celltrion Healthcare is contributing in the same line with their innovations to develop more treatment alternatives that could improve the lives of patients with IBD, in the US. Their new research focuses on showcasing the capabilities of the all-new subcutaneous formulation compared to the intravenous administration in terms of safety and effectiveness of the drugs. As stated by the company, with these administrations, increasing the accessibility to improved treatment options for patients would be possible.

Reduced Drugs Prices in Developed Nations to Further Trigger the Application of Biosimilars

Leading economies such as the United States are seen indulging in reducing prices for drugs to improve the accessibility of drugs. Owing to this scenario, biosimilars could offer patients an access to cost-effective yet high-quality therapeutic options. Moreover, United States is seen preparing to advance biosimilars and the FDA’s new program for educating doctors about biosimilars would further open new opportunities for these drugs. With nearly 3 million IBD patients in United States, these actions would help transform the way IBD patients are treated.

View Full Report with Table and Content@ https://www.marketresearchhub.com/report/physician-perspectives-2017-biosimilar-use-in-ibd-report.html

The research report provides a holistic understanding of the capabilities of the biosimilars to providing effective accessibility to the patients suffering from IBD including ulcerative colitis and CD. The inclusion of familiarity with biosimilar IFX and the anticipated application of biosimilars including IFX and ADA help is evaluating the potential of the drugs.

The report also provides the concerns associated with biosimilars to comprehend the possibilities of the drug with respect to every aspect that surrounds it. The inclusion of findings from the survey, analysis, overview of the methodology, and responder demographics in the study allow the reader to evaluate the potential of using biosimilars in place of the conventional drugs. With the meaningful insights by over 100 specialists in IBD, recommendations from healthcare analysts, expert overview over the trends shaping the future management of IBD, and cost-effective support, the research study is a complete guide when it comes to examining the competency of biosimilars.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research   and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us         

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

This release was published on openPR.